Search
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Synonyms: 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile, 1,6-DIAZASPIRO(3.4)OCTANE-1-PROPANENITRILE, 3-METHYL-.BETA.-OXO-6-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (3S,4R)-Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalTislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]
Categories: Programmed Death Receptor-1 Blocking Antibody, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsUlobetasol
go.drugbank.com/drugs/DB00596ApprovedUlobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol].
Mixtures: Ultravate X, Ultravate XCategories: Corticosteroid Hormone Receptor AgonistsDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalIt is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … Multidrug-resistant tuberculosis may also require more than 2 years of chemotherapy and second-line therapies with narrow therapeutic index [A31968].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (2R)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-B)(1,3)oxazole, (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazoleTridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections.
Categories: P-glycoprotein substratesIndomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigational-3-acetic acid. … NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole
Mixtures: INDOBIOTIC GOZ DAMLASI, 5 MLCategories: P-glycoprotein inhibitors, P-glycoprotein substratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalcan produce a broad adaptative and innate immune cell inhibitory activity. … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPhenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnPhenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. … It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Mixtures: TERA F, TERA FCategories: Adrenergic beta-2 Receptor Agonists, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesRagweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.